Product Reports Resources Pricing Login Book a demo

UniQure

Biotech & Life Sciences · Amsterdam, Netherlands · Founded 1998 · IPO 2014

Delivering on the promise of gene therapy - single treatments with potentially curative result for patients with severe genetic diseases.

Valuation $2.28B
Revenue $21M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue
Knowledge graph
News uniQure launches $150M public offering to fund gene therapy pipeline Jun 22, 2026 News Kurma Partners closes €215M Biofund IV, crosses €1B in assets under management Apr 23, 2026 Market map Healthy ageing (silver health, elderly care, longevity) Europe

Talent graph

UniQure's talent

Book a demo to see the people
Employees mapped 319 incl. 4 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 10 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 10 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

5 investors on UniQure's cap table

Sourced from Dealroom's funding history.

Series B+ 5 investors entered at this stage
Forbion Capital Partners
Coller Capital
Amsterdam UMC
University of Amsterdam
Chiesi Pharmaceuticals

UniQure mafia

Startups founded by UniQure alumni

Former UniQure employees who went on to start their own companies. Sorted by Dealroom signal score.

NewAmsterdam PharmaEst. 2019
Johannes J. P. KasteleinUnited States
Signal score90
VectorY TherapeuticsEst. 2020
PKPavlina Konstantinova,Netherlands
Signal score89
VarmXEst. 2016
Pieter ReitsmaNetherlands
Signal score86
Fuse VectorsEst. 2022
Benjamin BlahaDenmark
Signal score69
Frontera TherapeuticsEst. 2019
Yong DaiUnited States
Signal score64
Cardior PharmaceuticalsEst. 2016
Claudia UlbrichGermany
Signal score64
SalioGen TherapeuticsEst. 2020
Joseph J. HigginsUnited States
Signal score61
Synerkine PharmaEst. 2018
HPHans PreustingNetherlands
Signal score59
G7 TherapeuticsEst. 2013
Jörn AldagSwitzerland
Signal score56
HypherdataEst. 2019
Jana MiniarikovaNetherlands
Signal score52

Book a demo to explore the full alumni network →

Global footprint

Where UniQure has talent and traffic

Workforce by country
8 countries with
team presence
🇳🇱 Netherlands53.3%
🇺🇸 United States40.7%
🇨🇭 Switzerland3.9%
🇬🇧 United Kingdom0.6%
🇩🇪 Germany0.4%
Top 5 of 8 shown
Web traffic by country
17K monthly visits
across markets
🇺🇸 United States37.6%
🇦🇺 Australia12.9%
🇮🇳 India11.2%
🇬🇧 United Kingdom10%
🇫🇷 France5.9%
Top 5 markets shown

Patent intelligence

$76M patent portfolio · 42 active families

Estimated portfolio value
$76M
3.4% of market cap · comparable to top peer Akebia Therapeutics ($80M)
42 active patent families
Where UniQure innovates Acetic acidAlcoholAromatic hydrocarbonBioinformaticsCapsid

Where UniQure concentrates vs peers

Each axis is a top-10 topic across UniQure and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about UniQure

An AI-synthesized read of the highest-engagement posts about UniQure on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See UniQure on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles